The JunHe team possesses in-depth knowledge of the life science sector. They are able to provide services in a wide range of areas.

-The Legal 500

Life Sciences and Healthcare

At JunHe, we have been counseling domestic and foreign companies on their investments in the life sciences and healthcare sector in China since the 1990s. After thirty years of practice, JunHe is one of the few full-service law firms in China with a proven track record in this sector with expertise in the entire life cycle of medical products and services. We render quality services to all stakeholders in the industry. Our expertise and extensive experience in the sector are illustrated by the pioneering deals we have helped our valued clients achieve.

Our Team

Our life sciences and healthcare practice group comprises professionals from multidisciplinary practices, including dozens of partners and approximately 100 associates. Our life sciences and healthcare team of lawyers has vast experience in advising clients in the areas of mergers and acquisitions, capital markets, private equity/venture capital, intellectual property, compliance and dispute resolution. They have been involved in many high profile transactions and have represented the most active clients in the life sciences and healthcare sectors, offering them value-added, creative and practical legal solutions.

We offer our clients legal capabilities and services across the whole industry chain of pharmaceutical products, including:

- Drug discovery and patent application;
- · Drug-diagnostic and medical device co-development;
- · Preclinical research services;
- Design, management, filing and technical cooperation of clinical trial plans;
- IP licensing and transfer in every stage of drug and medical device development;
- Drug and medical device registration and compliance consulting;
- · Commercialization, manufacturing, marketing, sale and distribution of drugs and medical devices;
- Lifecycle compliance consulting for pharmaceuticals and medical devices;
- Drug and medical device adverse events and recalls, civil claims by patients and clinical trial participants; and
- · Government investigations, administrative penalties and dispute resolution services.

We advise life sciences and healthcare companies regarding issues in every stage of the life cycle, including:

- · Incubation and acceleration of new enterprises and products;
- Establishment of, and license applications for various life sciences and healthcare companies;
- · Angel investment and seed funding;
- Corporate restructuring, including the restructuring of red-chip structures and the restructuring of dismantled red-chip structures;
- Design and implementation of employee incentive plans;
- · Corporate mergers and acquisitions, joint ventures and collaborations;

JunHe, founded in Beijing in 1989, is one of the first private partnership law firms in China. Since its establishment, JunHe has grown to be a large and recognized Chinese law firm. The firm has twelve offices around the world and a team comprised of more than a thousand professionals. Our Departments



The team is highly professional and demonstrates particular strength in assisting clients with negotiations. Serious and dedicated attitude.

—The Legal 500

- Early-stage venture capital investments and subsequent pre-IPO private equity financing;
- Domestic and overseas IPOs on China's A-share market, the HKEx Main Board, NYSE and Nasdaq;
- Post-IPO asset restructuring, acquisition, going private and delisting of listed companies, and relisting of delisted companies on the STAE market;
- PIPE, SPAC, back door listings and spin-offs;
- Debt restructuring of public or private companies;
- · Corporate dissolution, liquidation and bankruptcy;
- Various dispute resolutions in connection with the foregoing matters; and
- Providing general legal counseling services for the day-to-day operation of life sciences and healthcare companies.

We represent all types of businesses in the life sciences and healthcare industry, such as:

- Multinational and major domestic companies in the pharmaceutical and medical industries;
 - Biotechs, biopharmas and big pharmas;
- Medical device (including IVD) R&D and production enterprises;
- Cosmetics, medical beauty products, digital medical products R&D and production enterprises;
- Equipment production, API and intermediate production companies in the pharmaceutical and medical industries;
- Contract research organizations (CRO) covering various stages of innovative drug research and development;
- Contract development and manufacturing organizations (CDMO) and contract manufacturing organizations (CMO);
- Contract sales organizations (CSO);
- Pharmaceutical distribution enterprises;
- Service providers of pharmaceutical inspections;
- Various healthcare facilities, such as full-service hospitals, specialty hospitals, chain medical examination institutions, medical clinics and on-line clinics;
- Various physical pharmacies and on-line pharmacies; and
- Domestic and foreign investors and financial advisors focused on investments in the life sciences and healthcare sector.

We provide a full range of legal services to meet the needs of our clients across all aspects of life sciences and healthcare issues:

- Legal counseling on general corporate matters;
- Legal advice on transactions and the design of transaction structures;
 - · Legal due diligence;
- Drafting and negotiation of transaction documents;
- Assisting in closing;
 - Post-closing integration;
 - Dispute resolution;
 - Issuing legal opinion;
 - Design and implementation of employee incentive plans;
 - · Issuing legal opinion on IPO projects;
 - Providing legal advice and assistance in government investigations;
 - Consulting, internal investigations and assistance with respect to corporate compliance in matters including but not limited to pharmacovigilance compliance, anti-commercial bribery, data security and privacy protection, EHS audits, antitrust, and human genetic resources compliance; and
 - Merger control notifications and legal advice on other antitrust matters.

Deals of the Year - BeiGene's USD 3.2 bn IPO on Star Market 2022

Deals of the Year - ByteDance's USD 1.4 bn Acquistion of Amcare

Deals of the Year - Abogen Therapeutics Series C and C+ Financing

2022 Deals of the Year - AstraZeneca, Aosaikang Patent Infringement Dispute

2022 Deals of the Year -Grifols Investmented in Shanghai RAAS through shares Swap 2020

Deals of the Year -RemeGen's Hong Kong Listing 2020

Deals of the Year - JD Health's USD \$1 billion series A Financing 2019 China Business Law Deals of the Year

Law Firms of the Year -Healthcare, Pharma & Life Sciences 2022

China Business Law Awards

Equity Deal of the Year -BeiGene's IPO 2022

ALB Hong Kong Law Awards

Deals of the Year - Shanghai -Banking and Finance -China Biologic Products Holdings USD 4.8 billion Take-private Financing 2022

IFLR 1000 China Awards

Healthcare Law Firm of the Year 2021

ALB China Law Awards

Merger Control Filing for Acquisition of Pfizer's Consumer Healthcare Business by GlaxoSmithKline 2020

Global Competition Review , Merger Control Matter of the Year for Asia-Pacific/Middle East/Africa

Deals of the Year - Harbin Pharma's \$300M Investment in GNC 2018

PRC Firm of the Year -Healthcare & Life Sciences 2017 China Law & Practice Awards